Skip to main content

Table 5 Liver damage and seroprevalence of hepatitis C antibodies (HCVAb)

From: Anti-hepatitis C antibody carriage and risk of liver impairment in rural-Cameroon: adapting the control of hepatocellular carcinoma for resource-limited settings

 

HCVAb

OR [95%CI]

p-value

Positive

(N = 48)

Negative

(N = 258)

 

n (%)

n (%)

ALT

Abnormal

32(66.67)

91 (35.27)

3.67[1.91; 7.05]

0.0001

Normal

16 (33.3)

167 (64.73)

AST

Abnormal

31(64.58)

113(43.8)

2.34[1.23; 4.44]

0.009

Normal

17 (35.42)

145 (56.20)

ALT + AST

Abnormal

30 (62.5)

63 (24.4)

3.90 [1.96; 7.79]

0.0001

Normal

15 (31.25)

123 (47.67)